Retatrutide vs Syn-Ake
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Retatrutide
Retatrutide (LY3437943) is a first-in-class triple agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. Developed by Eli Lilly, it is currently in Phase 3 clinical trials and has demonstrated the highest weight loss of any obesity medication to date — up to 28.7% body weight reduction at 48 weeks. The triple-receptor mechanism represents the next evolution beyond dual agonists like tirzepatide.
Full details →Syn-Ake
Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a synthetic tripeptide that mimics the effect of Waglerin-1, a peptide found in Temple Viper venom. It's used in cosmetics for anti-wrinkle effects.
Full details →Side-by-Side Comparison
| Aspect | Retatrutide | Syn-Ake |
|---|---|---|
| Mechanism | Retatrutide is a synthetic peptide that activates three incretin/metabolic hormone receptors: (1) GLP-1 receptor — appetite suppression, insulin secretion, delayed gastric emptying, (2) GIP receptor — enhanced insulin sensitivity, improved fat metabolism, (3) Glucagon receptor — increased energy expenditure, hepatic fat mobilization, thermogenesis. The glucagon receptor component is the key differentiator, adding an energy-expenditure mechanism absent from GLP-1 and dual GIP/GLP-1 agonists. The molecule uses a C20 fatty diacid for albumin binding, enabling once-weekly dosing. | Acts as a competitive antagonist at the nicotinic acetylcholine receptor, reducing muscle contractions similar to Botox but through a different mechanism. Provides muscle-relaxing effects when applied topically. |
| Typical Dosage | Phase 2 trial doses: 0.5 mg, 4 mg, 8 mg, and 12 mg weekly. The 12 mg dose produced maximum weight loss (28.7%). Phase 3 trials are evaluating doses up to 12 mg. Dose escalation schedule similar to other GLP-1s (start low, increase every 4 weeks). Final approved dosing not yet established — Phase 3 trials ongoing. | Topical: 1-4% concentration in serums or creams. Applied 1-2 times daily to target areas like forehead and crow's feet. |
| Administration | Subcutaneous injection, once weekly. Phase 3 trials use pre-filled single-dose pens. Not yet commercially available — estimated FDA approval ~2027-2028. | Topical application only. Should be applied to clean skin. Often combined with other anti-aging peptides for synergistic effects. |
| Side Effects | Phase 2 data: nausea (up to 25%), diarrhea (up to 22%), vomiting (up to 15%), constipation, decreased appetite. GI side effects were dose-dependent and generally mild-to-moderate. Lower rates of nausea compared to semaglutide, potentially due to GIP component. Increased heart rate observed at higher doses. | Generally well-tolerated topically. Rare reports of mild skin irritation or sensitivity. |
| Best For |
Key Differences
Unique to Retatrutide:
Unique to Syn-Ake:
Detailed Analysis
Commonalities
Retatrutide and Syn-Ake are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose Retatrutide for Fat Loss. Choose Syn-Ake for Skin Health & Aesthetics.
Ready to Learn More?
Looking for trusted sources?